TABLE 2.

Comparison of IC₅₀ values among three SARS-CoV-2 variants in Calu-3 cells

Compound	A		B.1.1.7		B.1.351
	Mean ± SDa (μM)		Mean ± SDa (μM)	P valueb	Mean ± SDa (μM)	P valueb
Camostat	0.102 ± 0.023		0.108 ± 0.006	0.797	0.170 ± 0.013	0.064
Nafamostat	0.016 ± 0.003		0.018 ± 0.009	0.650	0.024 ± 0.000	0.065
Aprotinin	0.696 ± 0.333		0.930 ± 0.108	0.457	1.037 ± 0.364	0.347
Bromhexine	12.42 ± 0.378		12.20 ± 0.392	0.836	29.44 ± 13.89	0.285
Niclosamide	1.587 ± 0.119		1.383 ± 0.179	0.475	1.210 ± 0.021	0.045
Ciclesonide	6.258 ± 1.384		5.541 ± 0.157	0.528	8.980 ± 2.235	0.462
Remdesivir	0.730 ± 0.061		0.423 ± 0.050	0.036	0.726 ± 0.052	0.652
Molnupiravir	1.979 ± 0. 161		1.705 ± 0.714	0.916	3.403 ± 0.030	0.007
EIDD-1931	0.292 ± 0.067		0.245 ± 0.014	0.476	0.351 ± 0.070	0.355

^aMean of 50% inhibitory concentration (IC₅₀) values ± standard deviation (SD) of duplicate IC₅₀ values.

^bStudent’s t test results by comparing IC₅₀ values of A to IC₅₀ values of B.1.1.7 or B.1.351.